NCT07342829

Brief Summary

POQS-Boosted is a prospective observational study during which individuals who received Booster vaccination against mpox with the MVA-BN vaccine will be invited to provide biological samples at multiple times over the course of two years.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
95

participants targeted

Target at P50-P75 for all trials

Timeline
26mo left

Started Jan 2026

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress13%
Jan 2026Jun 2028

First Submitted

Initial submission to the registry

January 6, 2026

Completed
9 days until next milestone

First Posted

Study publicly available on registry

January 15, 2026

Completed
Same day until next milestone

Study Start

First participant enrolled

January 15, 2026

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2028

Last Updated

January 20, 2026

Status Verified

January 1, 2026

Enrollment Period

2.5 years

First QC Date

January 6, 2026

Last Update Submit

January 15, 2026

Conditions

Monkeypox (Mpox)

Keywords

mpoximmunologyvaccinationbooster

Outcome Measures

Primary Outcomes (1)

  • Orthopoxvirus-specific serum binding and neutralising antibody titre

    To describe the evolution of the orthopoxvirus-specific serum antibody response up to two years after MVA-BN booster vaccination

    from enrollment to the end of follow up at 2 years

Secondary Outcomes (2)

  • Orthopoxvirus-specific systemic T- and B cell-mediated immune responses to MPXV

    from enrollment up to 2 years

  • MPXV-specific IgA in saliva and anorectal samples; T and B cell-mediated immune responses to MPXV, measured on saliva and anorectal samples

    from enrolment up to two years

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Individuals who received MVA-BN booster vaccination will be asked to participate in "POQS-Boosted"

You may qualify if:

  • Is scheduled to receive a booster dose of MVA-BN
  • ≥18 years
  • Willingness to provide written informed consent
  • Willingness to follow the study schedule

You may not qualify if:

  • \. Past or current MPXV infection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institute of Tropical Medicine

Antwerp, 2000, Belgium

Location

Biospecimen

Retention: SAMPLES WITH DNA

Serum; Saliva; Anorectal swabs; PBMCs

MeSH Terms

Conditions

Mpox, Monkeypox

Condition Hierarchy (Ancestors)

Poxviridae InfectionsDNA Virus InfectionsVirus DiseasesInfectionsPrimate DiseasesAnimal DiseasesRodent Diseases

Study Officials

  • Laurens Liesenborghs, MD

    Institute of Tropical Medicine Antwerp

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Christophe Van Dijck, PhD

CONTACT

+32 3 345 58 65cvandijck@itg.be

Clinical Trials Unit Antwerp

CONTACT

+32 3 247 66 66studies@itg.be

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
2 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 6, 2026

First Posted

January 15, 2026

Study Start

January 15, 2026

Primary Completion (Estimated)

June 30, 2028

Study Completion (Estimated)

June 30, 2028

Last Updated

January 20, 2026

Record last verified: 2026-01

Locations

BE(1)